These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33938166)

  • 41. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
    Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
    Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
    Glutsch V; Grän F; Weber J; Gesierich A; Goebeler M; Schilling B
    J Immunother Cancer; 2019 Jul; 7(1):181. PubMed ID: 31300044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
    Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.
    Mandalà M; Tondini C; Merelli B; Massi D
    Am J Clin Dermatol; 2017 Oct; 18(5):597-611. PubMed ID: 28432648
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Option Value of Innovative Treatments for Metastatic Melanoma.
    Thornton Snider J; Seabury S; Tebeka MG; Wu Y; Batt K
    Forum Health Econ Policy; 2018 Jun; 21(1):. PubMed ID: 30210050
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
    Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL
    J Clin Oncol; 2018 Jun; 36(17):1658-1667. PubMed ID: 28981385
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nivolumab in combination with ipilimumab for the treatment of melanoma.
    Somasundaram R; Herlyn M
    Expert Rev Anticancer Ther; 2015; 15(10):1135-41. PubMed ID: 26402246
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ipilimumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):811-26. PubMed ID: 27403706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research.
    Kidwell KM; Postow MA; Panageas KS
    Clin Cancer Res; 2018 Feb; 24(4):730-736. PubMed ID: 28835379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
    Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
    Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
    Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

  • 58. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.
    Gibney GT; Hamid O; Lutzky J; Olszanski AJ; Mitchell TC; Gajewski TF; Chmielowski B; Hanks BA; Zhao Y; Newton RC; Maleski J; Leopold L; Weber JS
    J Immunother Cancer; 2019 Mar; 7(1):80. PubMed ID: 30894212
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma.
    Mennini FS; Bini C; Marcellusi A; Del Vecchio M
    Clin Drug Investig; 2018 Oct; 38(10):967-976. PubMed ID: 30143953
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
    Warner AB; Postow MA
    Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.